3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
7
Recruiting
4
Active not recruiting
4
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
15
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
4
Uveal Melanoma
3
Sarcoma
3
Prostatic Neoplasms
3
Neoplasm Metastasis
3
Pancreatic Neoplasms
2
Lung Neoplasms
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Brain Neoplasms
2
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous-Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Diseases
1
Osteosarcoma
1
Neoplastic Cells, Circulating
1
Neoplasms, Unknown Primary
1
Neoplasms by Site
1
Nasopharyngeal Carcinoma
1
Metastatic Microsatellite Stable Colorectal Cancer
1
Kidney Neoplasms
1
Hypoxia
1
Histiocytoma, Malignant Fibrous
1
Head and Neck Neoplasms
1
Interventions
toripalimab
4
pembrolizumab
4
Gemcitabine
4
tislelizumab
2
durvalumab
2
Nivolumab
2
Cisplatin
2
Carboplatin
2
AZD4547
2
tipifarnib
1
tesetaxel
1
sapanisertib
1
regorafenib
1
pyrotinib
1
nintedanib
1
famitinib
1
disitamab vedotin
1
camrelizumab
1
bintrafusp alfa protein, human
1
atezolizumab
1
anlotinib
1
aldesleukin
1
advexin
1
Vitamin B 12
1
Trastuzumab
1
Taxes
1
Surgical Procedures, Operative
1
Saline Solution
1
Resistance Training
1
Pemetrexed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Carcinoma, Transitional Cell
×
Ipilimumab
×
Clear all
NCT03219775
2021-11-03
TITAN-TCC
AIO-Studien-gGmbH
Phase 2
Unknown
169 enrolled